Skip to content
中文产业新闻评分16Chinese source

2026 EASD口头报告｜恒瑞医药GLP-1/GIP双受体激动剂瑞普泊肽注射液治疗肥胖合并PMOS Ⅱ期研究亮相

2026 EASD口头报告︱恒瑞医药GLP-1/GIP双受体激动剂瑞普泊肽注射液治疗肥胖合并PMOS Ⅱ期研究亮相

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.